GI Cancer Drugs

Question 1

Bevacizumab MOA

Answer 1

rhuMAb-VEGF

Question 2

Bevacizumab AE

Answer 2

Bleeding, GI perforation, wound dihescence

Question 3

Bevacizumab use

Answer 3

colorectal

Question 4

Capecitabine MOA

Answer 4

Oral pro-drug metabolized to 5-FU

Question 5

Capecitabine AE

Answer 5

CV, neurologic & hematologic toxicities

Question 6

Capecitabine CI

Answer 6

Renal dysfunction

Question 7

Capecitabine PK

Answer 7

Dihydropyrimidine dehydrogenase (DPD) deficiency prevents metabolic activation

Question 8

Cetuximab MOA

Answer 8

rh/mMAb-EGFR

Question 9

Cetuximab AE

Answer 9

Cardiac & respiratory arrest, sudden death

Question 10

Cetuximab use

Answer 10

Colorectal

Question 11

Cisplatin MOA

Answer 11

Forms DNA intrastrand crosslinks and adducts

Question 12

Cisplatin AE

Answer 12

BM suppression, platinum reaction; nephrotoxic & ototoxic

Question 13

Docetaxel MOA

Answer 13

Microtubule stabilizer inhibiting depolymerization

Question 14

Docetaxel AE

Answer 14

↑ in tx mortality with NSCLC, edema

Question 15

Docetaxel CI

Answer 15

hepatic disease

Question 16

Erlotinib MOA

Answer 16

EGFR-TKI

Question 17

Erlotinib AE

Answer 17

GI, bleeding, ↑LFTs, ocular, interstitial lung

Question 18

Erlotinib use

Answer 18

pancreas

Question 19

fluorouracil (5-FU) MOA

Answer 19

Pyrimidine antimetabolite that inhibits thymidylate synthase (TS) & interferes with RNA synthesis & function. Also has some effects on DNA

Question 20

Fluorouracil (5-FU) AE

Answer 20

DPD deficiency → enhanced neurotoxicity

Question 21

Gemcitabine MOA

Answer 21

DNA polymerase inhibitor via incorporation of triphosphate form during DNA synthesis

Question 22

Gemcitabine AE

Answer 22

BM suppression, infection, peripheral neuropathy

Question 23

Gemcitabine PK

Answer 23

take before meal

Question 24

IFN-alpha MOA

Answer 24

Enzyme activation following cell surface receptor binding and tyrosine kinase activation

Question 25

IFN-alpha AE

Answer 25

neuropsychiatric events

Question 26

IFN-alpha use

Answer 26

GI carcinoid

Question 27

Imatinib MOA

Answer 27

Oral TKI as adjuvant treatment following complete resection of Kit (CD117) positive GIST

Question 28

Imatinib AE

Answer 28

GI common, CHF in some

Question 29

Imatinib use

Answer 29

GIST

Question 30

Mitomycin MOA

Answer 30

mono or bi functional alkylating agent

Question 31

Mitomycin AE

Answer 31

BM suppression, thrombocytopenia, HUS

Question 32

Octreotide MOA

Answer 32

Somatostatin analog; reduces duodenal bicarbonate, amylase, reduces gastric acidity, inhibits gallbladder contractility and bile secretion, inhibits meal-induced increases in superior mesenteric artery and portal venous blood flow

Question 33

Octreotide AE

Answer 33

monitor blood glucose, dose-dependent diarrhea

Question 34

Octreotide use

Answer 34

GI carcinoid

Question 35

Sufitinib MOA

Answer 35

Inhibitor of >80 receptor tyrosine kinases (RTKs)
∙ PDGRF-a/b, VEGF-R1/2/3, KIT, FLT-3
∙ CSFR-1R & RET

Question 36

Sufitinib AE

Answer 36

thrombocytopenia and bleeding, QT prolongation & GI complications

Question 37

Sufitinib use

Answer 37

GIST

Question 38

Trastuzumab MOA

Answer 38

HER-2/neu antibody; HER2 is downregulated, cyclin-dependent kinase inhibitor p27 accumulates, and cell cycle arrest occurs. Also inhibits the constitutive HER2 cleavage/shedding mediated by metalloproteases, which may correlate with the clinical activity

Question 39

Trastuzumab AE

Answer 39

LVEF dysfunction & cardiomyopathy

Question 40

Trastuzumab use

Answer 40

gastric